127 related articles for article (PubMed ID: 37488476)
1. A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational study.
Yoshida H; Ohki T; Kanezaki M; Teratani T; Sato S; Obi S; Sato T; Akamatsu M; Uchino K; Taniguchi H
BMC Gastroenterol; 2023 Jul; 23(1):250. PubMed ID: 37488476
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
J Gastroenterol; 2019 Feb; 54(2):171-181. PubMed ID: 30105510
[TBL] [Abstract][Full Text] [Related]
3. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Shimizu T; Watakabe K; Enomoto N; Izumi N
PLoS One; 2019; 14(2):e0211122. PubMed ID: 30768601
[TBL] [Abstract][Full Text] [Related]
4. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
[TBL] [Abstract][Full Text] [Related]
5. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma.
Alkhouri N; Imawari M; Izumi N; Osaki Y; Ochiai T; Kano T; Bentley R; Trevisani F
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2600-2608.e1. PubMed ID: 32205226
[TBL] [Abstract][Full Text] [Related]
6. [Avoidance of platelet transfusion with readministration of lusutrombopag before radiofrequency ablation in hepatocellular carcinoma:a case report].
Kotani S; Kohge N; Tsukano K; Ogawa S; Yamanouchi S; Kusunoki R; Aimi M; Miyaoka Y; Fujishiro H
Nihon Shokakibyo Gakkai Zasshi; 2017; 114(10):1853-1859. PubMed ID: 28978885
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance.
Flamm SL; Peck-Radosavljevic M; Fukuhara T; Bentley R; Katsube T; Ochiai T; Kano T; Tsukimura E; Sasaki R; Osaki Y
Adv Ther; 2022 Sep; 39(9):4285-4298. PubMed ID: 35904722
[TBL] [Abstract][Full Text] [Related]
8. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study.
Nomoto H; Morimoto N; Miura K; Watanabe S; Takaoka Y; Maeda H; Sasaki T; Koyashiki Y; Kurata H; Numao N; Isoda N; Yamamoto H
BMC Gastroenterol; 2020 Dec; 20(1):427. PubMed ID: 33317473
[TBL] [Abstract][Full Text] [Related]
9. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Tanaka T; Sunago K; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Abe M; Joko K; Michitaka K; Hiasa Y
J Gastroenterol Hepatol; 2020 Feb; 35(2):299-304. PubMed ID: 31318996
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia.
Ishikawa T; Okoshi M; Tomiyoshi K; Kojima Y; Horigome R; Imai M; Nozawa Y; Iwanaga A; Sano T; Honma T; Yoshida T
Hepatol Res; 2019 May; 49(5):590-593. PubMed ID: 30602063
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.
Tsuji Y; Kawaratani H; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Takaya H; Shimozato N; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
Dig Dis; 2020; 38(4):329-334. PubMed ID: 31655803
[TBL] [Abstract][Full Text] [Related]
12. Lusutrombopag Reduces the Risk of Hemoperitoneum Caused by Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Compared with Platelet Transfusion.
Taki S; Ida Y; Tamai H; Maeshima S; Shimizu R; Shingaki N; Maekita T; Iguchi M; Kitano M
Dig Dis; 2024 Apr; ():. PubMed ID: 38663358
[TBL] [Abstract][Full Text] [Related]
13. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
Clin Gastroenterol Hepatol; 2019 May; 17(6):1192-1200. PubMed ID: 30502505
[TBL] [Abstract][Full Text] [Related]
14. Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient.
Sakamaki A; Watanabe T; Abe S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
Clin J Gastroenterol; 2017 Jun; 10(3):261-264. PubMed ID: 28324272
[TBL] [Abstract][Full Text] [Related]
15. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.
Ding Z; Wu H; Zeng Y; Kuang M; Yang W; Meng Z; Chen Y; Hao C; Zou S; Sun H; Liu C; Lin K; Shi G; Wang X; Fu X; Chen R; Chen Y; Liang R; Kano T; Pan H; Yang S; Fan J; Zhou J
Hepatol Int; 2023 Feb; 17(1):180-189. PubMed ID: 36258065
[TBL] [Abstract][Full Text] [Related]
16. Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease.
Sano Y; Morimoto M; Kobayashi S; Ueno M; Fukushima T; Asama H; Kawano K; Nagashima S; Tanaka S; Ohkawa S; Maeda S
Digestion; 2021; 102(4):654-662. PubMed ID: 32841939
[TBL] [Abstract][Full Text] [Related]
17. Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease.
Yoshida M; Tateishi R; Hiroi S; Hongo Y; Fujiwara M; Kitanishi Y; Iwasaki K; Takeshima T; Igarashi A
Adv Ther; 2022 Jan; 39(1):379-390. PubMed ID: 34748184
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.
Sato S; Miyake T; Kataoka M; Isoda K; Yazaki T; Tobita H; Ishimura N; Kinoshita Y
Intern Med; 2017 Nov; 56(21):2887-2890. PubMed ID: 28943563
[TBL] [Abstract][Full Text] [Related]
19. Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag.
Brown RS; Imawari M; Izumi N; Osaki Y; Bentley R; Ochiai T; Kano T; Peck-Radosavljevic M
JHEP Rep; 2021 Apr; 3(2):100228. PubMed ID: 33644726
[TBL] [Abstract][Full Text] [Related]
20. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
